AXSM News and Press, Axsome Therapeutics Inc. From 08/19/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Axsome Therapeutics (NASDAQ: AXSM ) are up more than 30% today on news that the biopharmaceutical company has received approval from the U.S. Food and Drug Administration (FDA) for a unique, first-of-its-kin...

Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) popped well into the green after the biopharma firm received approval for its depression disorder drug from the United States Food and Drug Administration. Shares of Bill.com Holdings, Inc. ( NYSE: BILL ) have also tracked highe...

The shares of Axsome Therapeutics ( NASDAQ: AXSM ) added ~19% in the pre-market trading Friday after the U.S. biopharma company announced the approval of Auvelity extended-release tablets for adults with the major depressive disorder (MDD). According to the company, Au...

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week 1 -4 AUVELITY uses the first new oral mechanism of action approved for major...

AXSOME THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM AXSOME THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick &...

Whenever a small drugmaker fails to earn approval for a new product, its shares are likely to drop. But these regulatory headwinds can sometimes create excellent buying opportunities in the volatile biotech industry, provided the company in question can address regulators' concerns and even...

Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q2 2022 Earnings Call Aug 09, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q2 2022 Earnings Call Transcript

Axsome Therapeutics (NASDAQ: AXSM) investors seem to be a hardy bunch, as they didn't let a mixed quarter dissuade them from trading up the company's stock. On a day when the S&P 500 index dipped a bit, Axsome's share price enjoyed a healthy rise of over 3% thanks to that qu...

Axsome Therapeutics, Inc. (AXSM) Q2 2022 Earnings Conference Call August 9, 2022 08:00 ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Founder, Chairman, Chief Executive Officer & President Lori Englebert - Executive Vice Pr...

Commercial-stage biopharma Axsome Therapeutics ( NASDAQ: AXSM ) fell ~8% in the pre-market even after the company exceeded Street forecasts with its Q2 2022 financials on Tuesday as the investors focus on the regulatory path for the company’s depression candidate AXS-...